A model for analyzing the cost of the main clinical events after lung transplantation.

BACKGROUND The aim of this project was to model clinically important events experienced by lung transplant patients (from the day after transplant to 5 years or death) and costs associated with these events, and to assess the economic impact of different immunosuppression therapies. METHODS The population comprised 356 lung transplant patients (223 heart-lung, 102 single lung and 31 double lung) transplanted between April 1984 and December 1997. All patients received a cyclosporine-based triple-immunosuppression protocol. We designed a Markov model that included 3 time periods (0 to 6, 7 to 12, and 13 to 60 months), 5 clinical states (well, acute rejection, cytomegalovirus infection, non-cytomegalovirus infection and bronchiolitis obliterans syndrome), and death. For the well state, cost elements were immunosuppression, prophylaxis, and routine clinic visits. For all other states, cost elements were diagnosis, treatment, and bed days/visits. We excluded costs of the procedure. RESULTS The monthly costs associated with the well state decreased over time, from pound sterlings 1,778 ($2,658) in the first 6 months to pound sterlings 503 ($752) in months 7 to 12 and pound sterlings 350 ($523) after the first 12 months. The cost per event of the acute states remained reasonably constant over the 3 periods: pound sterlings 1,850 ($2,766) for rejection, pound sterlings 3,380 ($5,053) for cytomegalovirus, and pound sterlings 2,790 ($4,171) for other infections. The average cost per patient, discounted at 6%, over 5 years was pound sterlings 35,429 ($52,966) (95% range, pound1,435 [$2,145] to pound67,079 [$100,283]). This estimate is most sensitive to changes in immunosuppression. Substituting tacrolimus for cyclosporine increased 5-year costs by 5%; substituting mycophenolate mofetil for azathioprine increased 5-year costs by 26%. CONCLUSIONS This model is valuable in estimating the effect of new immunosuppression agents on the costs of follow-up care.

[1]  G. Raghu,et al.  The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. , 1995, Chest.

[2]  R. Jacobs,et al.  A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  D. Kitzmann,et al.  An economic analysis of kidney transplantation. , 1998, The Surgical clinics of North America.

[4]  R. Novick,et al.  The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report--1999. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  A. Laupacis,et al.  A study of the quality of life and cost-utility of renal transplantation. , 1996, Kidney international.

[6]  D Heng,et al.  Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  G. Patterson,et al.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  L. Sharples,et al.  A model for analyzing the cost of main clinical events after cardiac transplantation. , 1996, Transplantation.

[9]  J. Wolff,et al.  Economic analysis of Neoral in de novo renal transplant patients in Canada. , 1997, Clinical Transplantation.

[10]  L. Garrison,et al.  The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1997, Journal of the American Society of Nephrology : JASN.

[11]  G. Bonsel,et al.  Technology Assessment of the Dutch Lung Transplantation Program , 1998, International Journal of Technology Assessment in Health Care.

[12]  S. Pauker,et al.  Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. , 1991, Transplantation.

[13]  G. Klintmalm,et al.  The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. , 1995, Transplantation.

[14]  M. Koopmanschap,et al.  Lifetime costs of lung transplantation: estimation of incremental costs. , 1997, Health economics.

[15]  R. Morris,et al.  New immunosuppressive regimens in lung transplantation. , 1997, The European respiratory journal.

[16]  Se-Ge Ma,et al.  Cost-utility of lung transplantation: a pilot study. , 1997 .

[17]  J. Alexander,et al.  Economic costs of expanded criteria donors in renal transplantation. , 1998, Transplantation.

[18]  D. Manninen,et al.  An economic analysis of heart-lung transplantation. Costs, insurance coverage, and reimbursement. , 1993, The Journal of thoracic and cardiovascular surgery.

[19]  R. Speich,et al.  Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. , 1999, Transplantation.